Cancer ImmunoGeneTherapy

TEMferon: Tumor Immunotherapy by Autologous Hematopoietic-Stem-Cell Gene Transfer

We develop a gene transfer strategy into hematopoietic cells to target specific anti-tumor proteins. A definite vector delivers the gene into the cells. We use a combination of transcriptional and mediated control gene expression to selectively direct the anti-tumor proteins to the tumor area. Based on our exclusive mechanism, the immune system cells are reactivated and armed with a potent drug.

Genenta has been authorized to enter in a Ph I/II clinical trials in early Multiple Myeloma relapsing and newly diagnosed Glioblastoma Multiforme patients.

About Us

Genenta Science is a company developing a new generation of gene therapies based on transcriptional and mirRNA-mediated control.

LEARN MORE

Our Science

Using gene vectors, microRNA targets sequences and transgenes for preventing or reducing expression of the transgenes.

LEARN MORE

Our Pipeline

Genenta Science is leveraging its TEMferon technology platform to treat cancers using a novel immuno-gene therapy approach

LEARN MORE

News

March, 2015. Genenta Science banked an overall USD 11.0 million Series A round.

LEARN MORE